Study objective -To study the rate of progression to AIDS and to death, and the causes of death among intravenous drug users in Norway. Design -This was a prospective study. The study population was followed from diagnosis of HIV seropositivity until death or the end of the study period. The mean follow up was 56 months (range 1-73 months). Setting -Subjects were recruited from a public HIV test clinic and followed by linkage to the National AIDS Registry and the National Cause of Death Registry. Participants -A total of 131 HIV positive intravenous drug users were included. The study population represented 75% of all intravenous drug users who had been diagnosed as HIV positive in Norway before 1987. None were lost to follow up. Main results -Four years after study entry, 3% (95% confidence interval, 0, 6%) had developed AIDS, while 15% (95% CI, 9, 21%) had died. Of the 25 subjects who died during the follow up period, 21 died from unnatural causes. Drug overdose accounted for 17 of these deaths. AIDS was the cause of death of three subjects only. Age more than 30 years at entry to the study was associated with short survival. Conclusions -These results suggest that the progression rate to AIDS in intravenous drug users is slow.
The number of deaths from infectious diseases not included in the definition of AIDSI-2 and from drug overdose have increased in populations of intravenous drug users since the introduction of HIV.-9 These observations suggest that the impact of the HIV epidemic on mortality cannot be measured in terms of the number of AIDS related deaths alone. Deaths not classified as being caused by AIDS, but associated with advanced HIV disease, suggest not only that additional causes of death may be attributed to advanced HIV infection, but also that the progression rate to AIDS among intravenous drug users' 04 may have been underestimated.
This study aimed to estimate the progression rate to AIDS and the progression rate to death after HIV diagnosis in a cohort of 131 HIV positive intravenous drug users followed for more than four years. By comparing these estimates and by scrutinising forensic reports on the causes of death, possible sources of bias in estimating the AIDS progression rate were investigated. In addition, gender, age, and the duration of intravenous drug use before the diagnosis of HIV positivity are studied as cofactors of survival.
Methods

STUDY POPULATION
All intravenous drug users (n = 131) with Norwegian residency who were registered as HIV positive before 1987 at the Department of AIDS Prevention, Oslo City Department of Health and Environment were included in a prospective study from the date of diagnosis of HIV seropositivity. The study sample represented 75% (131 of 174) of all intravenous drug users who had been diagnosed as HIV positive in Norway and thereby registered in the National HIV Registry'5'6 before 1987. It is assumed that 80% of all intravenous drug users in Norway have been HIV tested. 17 In this study an intravenous drug user is defined as someone who has ever injected drugs after 1979. Individual data on drug preferences were not available. Based upon other studies of intravenous drug users in the Oslo area, it is assumed that approximately 90% used mainly heroin, whereas 10% used mainly amphetamine.'7 Methadone has not been used in the rehabilitation of intravenous drug users in Norway, except for a few cases. It is therefore believed that none, or very few, of this cohort received such treatment before or during the follow up period.
DIAGNOSIS OF HIV SEROPOSITIVITY
Almost all the subjects were HIV tested because of a self-experienced risk of being infected and after informed consent only. The serum analysis was performed at the Department of Microbiology, Ullev'al Hospital, Oslo, with the ELISA technique and verified with the western blot method.
The exact time of seroconversion was unknown. It is believed, however, that the HIV epidemic among intravenous drug users in Norway did not begin until the second half of 1983.18 Thus, it is unlikely that HIV seroconversion had occurred more than three and a half years before study entry for any subject in the cohort. HIV diagnosis was grouped as < 10 years, 10-14 years, and > 14 years.
CAUSES OF DEATH
The causes of death, according to the ICD-9 classification system were obtained from the National Death Registry.'9 AIDS deaths were confirmed by the National AIDS Registry.'5-'6
Unnatural deaths were confirmed by forensic autopsy at the Institute of Forensic Medicine, University of Oslo. The forensic autopsy included routine inspection of all external and internal organs and histological examination of brain, lung, heart, and liver tissue. When organ pathology which could not be diagnosed by routine examination was suspected, additional examination was performed. The brains were also examined at the Division of Neuropathology, Rikshospitalet, Oslo. To study drug overdose as a possible cause of death, the post mortem blood concentration of morphine and codeine was routinely measured at the National Institute of Forensic Toxicology, University of Oslo. The autopsies were performed one to three days after death. One per cent (0, 3%) was estimated to have died after one year; 10% (5, 15%) after three years; and 15% (9, 21%) after four years. The probability of survival and the probability of being AIDS free according to the duration of observation are shown in the Figure. 
Discussion
In this study of HIV positive intravenous drug users, the rate of progression to death was estimated to be more rapid than the progression rate to AIDS. The main cause of death was drug overdose, and age more than 30 years at entry to the study was associated with a rapid progression to death.
It has been shown that morphine impairs lymphocyte reactivity and increases HIV replication.2527 These findings suggest a more rapid progression to AIDS among intravenous drug users than in homosexual men. The existing estimates of the progression to AIDS among intravenous drug users,1014 including the results from this study, are either equal to or slower than the estimates for homosexual men.2>29 Four years after seroconversion, 13% (95% CI 7, 19%) of the homosexual men in the San Francisco hepatitis B vaccine trials were estimated to have developed AIDS.28 That finding agrees with the estimates of the progression rate to AIDS among homosexual men whose time of seroconversion was known in the MACS study. 29 In an Italian study of intravenous drug users, 17-8% were estimated to have AIDS after four years from seroconversion." In the later study, however, the mean follow up period was only 26 months.
In our study of intravenous drug users, however, only 3% (0, 6%) were estimated to have developed AIDS after four years. HIV seroconversion had occurred before study entry, and probably within three and a half years before enrolment.'8 Thus, the progression to AIDS after HIV diagnosis, as estimated in this study, represents a maximum estimate of the true progression rate to AIDS after HIV seroconversion. Age has been shown to be a cofactor of progression to AIDS.'2 The mean age in the men with a known time of seroconversion in the San Francisco hepatitis B vaccine trials was 30 years. In this study, the mean age was 26 years. It is unlikely that this difference in age can explain the difference in progression to AIDS.
Potential sources of bias in estimating the progression rate to AIDS have not been discussed a great deal in the published reports. Based on the design and the results of this study, the most important sources of biasselection bias in recruitment and in censoring, and underdiagnosis of AIDS -will be discussed.
Selection of subjects with slow HIV disease progression is unlikely to represent a major source of bias in this study, since most subjects are assumed to have been HIV infected less than two years before study entry. During the first two years after seroconversion very few are expected to develop AIDS. Before 1987 only two intravenous drug users had been diagnosed with AIDS in Norway. [15] [16] Selection bias in censoring might have occurred if HIV infection had been the underlying cause of death in those who died from causes unrelated to AIDS. A key concept in survival analysis, which is used for estimating the AIDS progression rate, is censoring. The subjects who die before developing AIDS, are considered as censored. In the analysis they are used as a part of the study population until censoring. An underlying assumption in the estimation of the progression rate to AIDS is that subjects who are censored have the same progression as the subjects who are not censored. Since unnatural death was the major cause of censoring in this study it could be postulated that such deaths may be attributed to HIV infection. The inflammatory reactions of the brain tissue, which were compatible with viral infection, may be associated with HIV disease. These findings have been seen more frequently in HIV positive than HIV negative intravenous drug users post mortem,30 and have been associated with early brain changes in HIV infection.3' The post mortem blood drug concentrations in all overdose deaths, however, were considered lethal. It is therefore uncertain whether the brain inflammation contributed to death. In an earlier study, higher post mortem drug concentrations were seen in HIV positive than HIV negative subjects who had died from drug overdose (1 05 ,umol/l versus 0 77 pumol/1).3Q 
